the TRACK-TBI Investigators IMPORTANCE Annually in the United States, at least 3.5 million people seek medical attention for traumatic brain injury (TBI). The development of therapies for TBI is limited by the absence of diagnostic and prognostic biomarkers. Microtubule-associated protein tau is an axonal phosphoprotein. To date, the presence of the hypophosphorylated tau protein (P-tau) in plasma from patients with acute TBI and chronic TBI has not been investigated.
T raumatic brain injury (TBI), considered as an event and/or a disease, initiates a complex pathophysiologic central nervous system cascade with acute effects and secondary insults that may lead to chronic functional, neurocognitive, and neuropsychiatric deficits.
1 Traumatic brain injury is classified according to its degree of severity (mild, moderate, and severe). In the United States, there are more than 3.5 million emergency department visits for TBI and more than 280 000 patients are hospitalized annually with TBI, with most of these classified as mild TBI (mTBI). There are also many more individuals with mTBI who never seek medical attention. More than 300 000 armed service members sustained TBI during combat and training from 2000 to 2014. 2 Approximately half of patients with TBI in the United States incur at least some shortterm disability. 3 Traumatic brain injury is associated with an increased risk of neurodegenerative disorders, such as Alzheimer disease, years or decades after injury. 4 In addition, repetitive mTBI is a risk factor for a neurodegenerative condition called chronic traumatic encephalopathy (CTE). [5] [6] [7] Chronic traumatic encephalopathy, which can be confirmed only by postmortem neuropathologic examination, is defined by the abnormal accumulation of hyperphosphorylated tau protein (P-tau) in neurons, astroglia, and cell processes distributed around small blood vessels at the depth of cortical sulci in an irregular pattern. 8 Tau protein is involved in regulating axonal microtubule assembly and disassembly. Posttranslational modifications of tau seem to precede brain tauopathy. These modifications include (1) hyperphosphorylation by multiple kinases, 9 (2) proteolysis by calpain and caspase, 10-12 and (3) oxidative modifications. [13] [14] [15] The abnormal P-tau protein forms paired helical filaments and progressively aggregates to form the main component of neurofibrillary tangles-a hallmark of tauopathy, including Alzheimer disease. 16 The major pathologic P-tau sites include, but are not limited to, threonine (Thr)181, serine (Ser)202, Thr205, Thr231, Ser396, and Ser404. 17 Abnormal accumulation of P-tau deposits in postmortem human brains are found years after repetitive mTBIs have been sustained. 18, 19 Single, simulated blast exposure and closed head injury in mice also result in increased deposition of P-tau. 20, 21 Amyloid β and/or tau levels are elevated in cerebrospinal fluid samples after severe TBI. [22] [23] [24] The use of a high-sensitivity assay platform (Simoa; Quanterix Corp) has permitted detection of acute and chronic tau elevations following mTBI in ice hockey players with sports-related concussion and military personnel with chronic postconcussive disorder symptoms. 25, 26 In contrast to the present report, those studies did not measure P-tau levels.
We recently used another high-sensitivity assay platform (multi-arrayed fiberoptics conjugated with rolling circle amplification [a-EIMAF]) and detected serum total (T)-tau and Ptau levels in patients with severe TBI, 27 as well as in 1-to 30-day mouse serum after single and/or repetitive mTBI. 21 However, to our knowledge, the profile of P-tau in blood samples in humans with mild and moderate TBI has yet to be defined. Incorporating the 3 tau indices to distinguish abnormal cranial computed tomography (CT) (pathoanatomic lesions) from normal CT findings would aid in the diagnosis and prognosis for acute TBI. Furthermore, to our knowledge, monitoring the 3 tau indices simultaneously in blood samples from patients with chronic TBI has not been done previously. Therefore, we used the a-EIMAF platform to examine whether P-tau and T-tau might be sensitive and specific biomarkers, using plasma from patient cohorts in the completed TRACK-TBI Pilot study.
Methods

TBI Patients and Biosample Collection
Four sites (3 level I trauma centers and 1 rehabilitation center) participated in this study. On arrival, participants were classified along the spectrum of neurotrauma severity (Glasgow Coma Scale [GCS)] score of 3-8, severe; 9-12, moderate; and 13-15, mild) and recruited into the multicenter, prospective TRACK-TBI Pilot study. 28 The TRACK-TBI Pilot study was conducted from April 1, 2010 ; patients with chronic TBI must have had sufficient neurologic impairment to be admitted to inpatient TBI rehabilitation units. 30 Single blood samples from patients with acute TBI across the full spectrum of injury severity (GCS, 3-8 [n = 25]); GCS, 9-12 [n = 8]; and GCS, 13-15 [n = 163]) were collected within 24 hours of injury. Among these patients with acute TBI, 108 (55.1%) had normal head CT (CT−) scans, while 88 (44.9%) showed CT abnormality (CT+) ( Table) . Single blood samples from 21 patients with chronic TBI were collected during the inpatient rehabilitation stay (Table) .
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Sample collection and processing for the TBI and healthy control cohorts were performed identically at all sites (including the commercial vendor for controls) according to the recommendations from the National Institutes of Health-National There were no significant differences in age or sex across the patient and control cohorts (Table) . In the 217 patients with TBI, 161 (74.2%) were men; mean age was 42.5 (18.1) years.
Plasma P-tau and T-tau Analysis by a-EIMAF
T-tau and P-tau a-EIMAF assay performance, lower limit of detection, lower limit of quantitation, and linearity range of standard curves for calculating T-tau and P-tau concentration are shown in eFigures 1 and 2 in the Supplement, respectively (eMethods in the Supplement).
Statistical Analysis
The T-tau and P-tau data for the acute and chronic TBI cohorts and controls were not normally distributed; thus, results are presented as median and interquartile range. Median differences for more than 2 groups were compared with the Kruskal-Wallis test. For 2-group comparisons, the nonparametric Mann-Whitney test was performed. The ability of T-tau level, P-tau level, and P-tau-T-tau ratio to distinguish patients with acute TBI vs controls, mild (GCS, 13-15) vs moderate/ severe (GCS, 3-12) TBI, normal vs abnormal cranial CT, 6-month outcomes on Glasgow Outcome Scale-Extended (GOS-E), and chronic TBI vs controls were assessed using the receiver operating characteristic (ROC) curve and associated area under the curve (AUC). Statistical analyses were performed using Prism, version 6 (GraphPad Software). Statistical significance was defined by an unpaired, 2-tailed P value ≤.05.
Results
Plasma P-tau levels, T-tau levels, and P-tau-T-tau ratios were determined for all patients with acute and chronic TBI. We have previously described detection of T-tau and P-tau in cerebrospinal fluid (EIMAF format) and serum (a-EIMAF format) from patients with severe TBI during the first 5 days after injury.
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Herein, we expand these findings by using plasma samples from 2 cohorts of the TRACK-TBI Pilot study and quantitate concentrations of T-tau and P-tau (eFigure 1 and eFigure 2 in the Supplement). In controls, we found no significant correlations between any of the 3 tau indices and age. For CT− patients, age had statistically significant Pearson correlation coefficients with P-tau level (r = 0.200, P = .04) and P-tau-T-tau ratio (r = 0.233, P = .02), but not with T-tau level (r = −0.075, P = .45). For CT+ patients, age had a statistically significant Pearson correlation coefficient with P-tau-T-tau ratio (r = 0.219, P = .04), but not for P-tau (r =0.157 ,P = .14) or T-tau (r = −0.082, P = .44) levels.
T-tau and P-tau Levels in TBI of Different Severities vs Controls
Plasma values of T-tau were 62.59 fg/mL for healthy controls, 79.21 fg/mL for patients with acute TBI with initial GCS 13 to 15, 84.10 fg/mL for GCS 9 to 12, and 79.21 for GCS 3 to 8 (P < .001 across groups) ( Figure 1A , eTable 1 in the Supplement). Median P-tau level was 20.85 fg/mL × 100 for healthy controls, 200.16 fg/mL × 100 for patients with acute TBI with GCS 13 to 15, 307.19 fg/mL × 100 for GCS 9 to 12, and 294.68 fg/ mL×100forGCS3to8(P < .001) ( Figure 1A , eTable 1 in the Supplement). P-tau-T-tau ratio ( × 10 000) for healthy controls was 30.94, compared with 263.19 for patients with acute TBI with GCS 13 to 15, 348.38 for GCS 9 to12, and 363.02 for GCS3to8(P < .001) ( Figure 1A , eTable 1 in the Supplement). Healthy controls compared with each severity group were significantly different for T-tau level, P-tau level, and P-tau-T-tau ratio (eTable 2 in the Supplement). P-tau values for GCS 13 to 15 vs GCS 9 to 12 and GCS 13 to 15 vs GCS 3 to 8 were significantly different, as were P-tau-T-tau ratios for GCS 13 to 15 vs GCS3to8(eTable2intheSupplement).
The ROC analyses showed the accuracy of all 3 plasma tau indices in distinguishing all acute TBI cases from healthy controls ( Figure 1B ). The AUC was 0.919 (P < .001) for T-tau level, 1.000 (P < .001) for P-tau level, and 1.000 (P < .001) for P-tau-T-tau ratio (eTable 3 in the Supplement, all TBI vs controls). All 3 plasma tau indices also showed accuracy in distinguishing mTBI (GCS 13-15) from normal control plasma ( Figure 1C ), with AUC = 0.916 (P < .001) for T-tau level, 1.000 (P < .001) for P-tau level, and 1.000 (P < .001) for P-tau-T-tau (eTable 3 in the Supplement, mTBI vs controls).
Because our results suggested that P-tau indices could distinguish mTBI (GCS 13-15) from severe and moderate TBI ( eT able2intheSupplement), we further applied ROC plots ( Figure 1D ). Plasma P-tau levels and P-tau-T-tau ratio showed fair accuracy for distinguishing mTBI (initial GCS 13-15) in patients with severe/moderate TBI (GCS≤12) (AUC = 0.711 and 0.748, respectively; both P < .001), whereas T-tau showed poor, but significant results (AUC 0.527, P = .04) ( Figure 1D ; eTable 4intheSupplement). 
Pathoanatomic Lesion Correlation
Neuroimaging using CT assessed the extent of the TBI, thereby allowing pathoanatomic classification. We assessed the ability of the 3 plasma tau indices to distinguish CT+ scan patients with TBI from those with normal findings on scans (CT-). As displayed in Figure 2A -C, median T-tau levels were 78.24 fg/mL for CT-and 83.13 fg/mL for CT+ scans (P < .001) ( Figure 2A ). P-tau levels were 1.45 fg/mL for CT-and 3.02 fg/mL for CT+ scans (P < .001) ( Figure 2B ), and the P-tau-T-tau ratio had a median of 0.0187 for CT-and 0.0363 for CT+ scans (P < .001) ( Figure 2C ). We also performed ROC analysis of 3 tau indices in distinguishing CT+ from CT-scans ( Figure 2D ). Both P-tau level and P-tau-T-tau ratio had excellent accuracy (AUC = 0.921 and 0.923, respectively), while T-tau had poor accuracy (AUC = 0.646) (eTable 5 in the Supplement). We compared the acute TBI tau indices of the mTBI (GCS 13-15) groups that had scans that were either CT+ (n = 61) or CT− (n = 102) with those of healthy controls (n = 20) (eFigure 3 in the Supplement). We identified significant group differences for T-tau level, P-tau level, and P-tau-T-tau ratio. Healthy controls could be distinguished from both CT+ and CT− cases based on all 3 tau indices (eFigure 3 in the Supplement). Furthermore, P-tau levels and P-tau-T-tau ratio could distinguish CT+ vs CT− scans among all patients with mTBI, although T-tau levels could not (eFigure 3 in the Supplement).
Finally, we investigated the correlation between acute TBI plasma tau indices and the Marshall CT scale. Owing to small individual counts, the more severe Marshall CT classifications (3-6) were grouped into a single category similar to previous approaches. [32] [33] [34] Marshall group comparisons showed statistical significance for all 3 tau indices (all P < .001) (eFigure 4 in the Supplement). We also found significant subgroup differences in Marshall CT scores: (1) T-tau level, 1 vs 2 (P < .001) and 1 vs 3 or higher (P < .05); (2) P-tau level, 1 vs 2 (P < .001) and 1 vs 3 or higher (P < .001); and P-tau-T-tau ratio, 1 vs 2 (P < .001) and 1 vs 3 or higher (P < .001) (eFigure 4 in the Supplement).
Outcome Correlation
Since P-tau might be related to tauopathy formation, we examined the ability of the plasma tau indices to predict outcome in patients with TBI using the GOS-E. Six-month outcome data were available in 137 patients (69.9%), 134 of whom had available plasma samples (68.3%) (Table) . A GOS-E score of 7 to 8 is considered a good outcome, and a GOS-E score of 6 or lower is considered a poor outcome. Figure 3B and C demonstrate that both acute TBI plasma P-tau level and P-tau-Ttau ratio have an inverse association with GOS-E. P-tau level (P = .001) and P-tau-T-tau ratio (P = .002) are lower in patients with TBI with a GOS-E of 7 to 8 vs those with a GOS-E of 6 or lower. In contrast, T-tau did not differ significantly between the 2 outcome groups (P = .27) ( Figure 3A ). In the good outcome (GOS-E, 7-8) column for P-tau level and P-tau-T-tau ratio, there appear to be 2 clusters (above or below 2 fg/mL Ptau level; and above or below 0.025 P-tau-T-tau ratio, respectively). These upper clusters closely match the respective ranges of P-tau level and P-tau-T-tau ratio for the poor outcome group (GOS-E, ≤6). This finding may suggest a natural clustering of acute post-TBI P-tau levels that are independent of our patient outcome measures (eg, GOS-E). In ROC curves for GOS-E of 7 to 8 (good outcome) vs GOS-E of 6 or lower ( Figure 3D ), the AUC for P-tau level (0.663) and P-tau-T-tau ratio (0.658) show that they are poor predictors of good outcome (eTable 6 in the Supplement, panel A). T-tau level failed to discriminate between those with good outcome (AUC = 0.552). In ROC curves for GOS-E of 4 or lower (poor outcome) vs GOS-E higher than 4 ( Figure 3E ), AUC for P-tau level (0.771) and for P-tau-T-tau ratio (0.777) shows that both of these P-tau indices are fair predictors of poor outcome (eTable 6 in the Supplement, panel B). The AUC for T-tau level (0.516) was again not significant.
Characterization of Plasma Tau Indices in Patients With Chronic TBI
For the chronic TBI cohort, the mean (SD) postinjury time at enrollment was 176.4 (44.5) days (range, 16.0-249.6 days). The plasma T-tau level, P-tau level, and P-tau-T-tau ratio were compared with those of healthy controls (n = 20) ( Figure 4A ). Median plasma T-tau level for chronic TBI was 69.48 vs 62.59 fg/mL for controls (P = .02); P-tau level was 97.30 fg/mL × 100 for chronic TBI vs 20.85 fg/mL × 100 for controls (P < .001); and the P-tau-T-tau ratio ( × 10 000) was 140.33 for chronic TBI vs 30.95 for controls (P < .001).
Finally, we performed ROC curves of plasma T-tau level, P-tau level, and P-tau-T-tau ratio from patients with chronic TBI vs healthy controls ( Figure 4B) . P-tau level (AUC = 1.000) and P-tau-T-tau ratio (AUC = 0.963) showed accuracy and outperformed T-tau level (AUC = 0.674) (eTable 7 in the Supplement).
Discussion
Biomarkers are emerging diagnostic tools for TBI. Since P-tau is pathologically linked to tauopathy found in Alzheimer disease, CTE, and other neurodegenerative diseases associated with TBI, 7 ,18,20 we examined peripheral T-tau and P-tau levels in the full spectrum of patients with TBI by using TRACK-TBI Pilot cohorts. 28, 30, 35 We demonstrate that plasma P-tau (P-Thr231) level, T-tau level, and P-tau-T-tau ratio are robustly higher in patients with all severities of acute TBI compared with healthy controls ( Figure 1A ). However, both P-tau indices differed according to TBI severity ( Figure 1D ). Although all patients with TBI and cranial CT+ scans had higher levels of all 3 tau indices than their CT− counterparts, P-tau levels and P-tau-T-tau ratio were much higher and predicted CT scan abnormality more accurately than did T-tau levels ( Figure 2 ). In patients with acute TBI, P-tau levels and P-tau-T-tau ratio outperformed T-tau level in identifying and possibly predicting good outcomes (Figure 3 ). Taken together, to our knowledge, this is the first report showing that acute plasma P-tau levels and the P-tau-T-tau ratio are superior diagnostic biomarkers for TBI than T-tau levels. Because of the likely differences in T-tau antigen standards and antibodies used in the different assay formats, making direct comparisons between the absolute plasma T-tau values from the acute mild and chronic TBI cohorts reported in our study with the previous reports on concussed ice-hockey players 25 and military personnel 26 is not possible.
Recent studies [35] [36] [37] have examined the use of blood biomarkers, which included ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), for the diagnosis and prognosis of TBI. Each of these biomarkers was effective alone and, in 1 study, 35 more specific and sensitive when combined in diagnosing TBI. However, a potential limitation of these studies is the short half-lives of UCH-L1 (<12 hours) and GFAP (<2 days) combined with the sensitivity limits of currently available assays. 36,38 P-tau and T-tau levels in cerebrospinal fluid have diagnostic value for identifying individuals with Alzheimer disease. 39-41 However, detection of these proteins in blood have been challenging owing to their low levels, which may now be overcome by the availability of new high-sensitivity assay platforms (single molecule array and a-EIMAF).
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We also found that plasma P-tau levels and P-tau-T-tau ratio in patients with chronic TBI are significantly higher than in healthy controls (Figure 4 ). Chronic traumatic encephalopathy was first described in 1928 by Martland 42 to describe the clinical tremors and impaired cognition that affected some boxers. Being "punch drunk" was later called "dementia pugilistica" 7 and then refined as CTE. 43, 44 Patients with CTE show progressively worsening dementia, poor executive function, confusion, anxiety, depression, and irritability that appear years after the initial trauma events. 45, 46 Omalu and colleagues 5, 19 reported neuropathologic lesions consistent with CTE in the brain of an American football player and a professional wrestler. Although CTE is associated with a history of repetitive mTBI or concussion, it is possible that a single but significant TBI event could also lead to the initiation of a tau phosphorylation cascade similar to those observed in repetitive mTBI. Consistent with this, our study showed elevations of plasma P-tau and T-tau levels in both the acute and the chronic phases of TBI. If, in fact, the tau phosphorylation cascade extends from the acute post-TBI phase into the chronic phase, it is possible that, in vulnerable individuals or those who experience successive TBI events, there may be sufficient cumulative tauopathy to initiate and/or accelerate the development of CTE. For detection of tauopathy in particularly vulnerable TBI cohorts (athletes and blast-exposed military), postmortem neuropathologic examination along with blood T-tau and P-tau level quantitation is ideal; however, conducting both is often infeasible. The development of specific tau tracers for positron emission tomographic imaging have enabled the analysis of the presence and intensity of tau pathology in patients 
T-tau P-tau P-tau− T-tau ratio Reference line
T-tau level (A), P-tau level (B), and P-tau-T-tau ratio, Glascow Outcome Scale-Extended (GOS-E) of 7 to 8 (good outcome) vs GOS-E of 6 or lower (poor outcome).
Median and first and third quartiles are shown (black bars). Statistical significance was based on Mann-Whitney test comparison. Receiver operating characteristic (ROC) curves for T-tau level, P-tau level, and P-tau-T-tau ratio in distinguishing ROC curves for good outcome GOS-E of 7 to 8 vs GOS-E of 6 or lower (D), and ROC curves for poor outcome GOS-E of 4 or lower vs GOS-E of 5 to 8 (E). eTable 6 in the Supplement provides detailed analysis. T-tau (fg/mL), P-tau (fg/mL × 100), or P-tau−T-tau (×10 000)
Chronic TBI Control T-tau P-tau P-tau−T-tau ratio A, T-tau level, P-tau, and P-tau-T-tau ratio. Median and first and third quartiles are shown (black bars). Statistical significance was based on Mann-Whitney test comparison; for the 2 subgroups (control vs chronic TBI), T-tau level (P = .02), P-tau level (P < .001), and P-tau-T-tau ratio (P < .001) are significantly different. B, Receiver operating characteristic (ROC) curve of plasma T-tau level, P-tau level, and P-tau-T-tau ratio for patients with chronic TBI vs healthy controls. eTable 7 in the Supplement provides detailed ROC analysis.
suspected of having tauopathies. 47 Thus, future studies correlating tau positron emission tomographic imaging data with the levels of P-tau and P-tau-T-tau ratios may offer a novel path for differential diagnosis, prognosis, and disease progression in patients with TBI.
5,6,19
Limitations
The fact that control samples were not collected at the study sites is a major limitation of the study. These commercially obtained control plasma samples had limited demographic and health status data of donors. Although all control and TBI patient samples collected for this study followed best practice guidelines, it is possible that the reliance on commercial control samples may have affected the comparisons between controls and patients with TBI due to possible differences in sample collection and processing. To address this limitation, we will further validate our T-tau and P-tau results using blood samples collected within 24 hours, at 1 to 2 weeks, and at 6 months after the TBI from approximately 1000 patients with TBI in the current TRACK-TBI study 48 supplemented with 2 groups of controls: friends/family controls (n = 300) and non-TBI orthopedic injury controls (n = 300). 36,49 Thus far, we were able to successfully contact and recruit a friend or family member for 92% of the case patients. This represented 46 friend controls and 54 family controls. An additional limitation is that our study focused on a single P-tau epitope (P-Thr231). It will be important to examine other major P-tau epitopes. Follow-up studies should seek to examine the time course of the plasma or serum levels of P-tau vs T-tau in the same patients in a larger longitudinal cohort study.
Conclusions
Acute T-tau and P-tau level elevations occur not only in severe/ moderate TBI, but also in patients with mTBI. We also identified the P-tau-T-tau ratio as an excellent biomarker index for TBI. We found that both acute P-tau levels and P-tau-T-tau ratio outperformed T-tau levels in discriminating by severity, CT abnormality, and outcome category. Finally, we report, for what we believe to be the first time, plasma P-tau level and P-tau-T-tau ratio elevations among patients with chronic TBI. Taken together, P-tau levels and P-tau-T-tau ratio might be useful biomarkers for both acute and chronic TBI. 
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eMethods. Detailed Methodology Detailed Plasma Sample Collection and Processing
Plasma samples from both the normal controls and TBI subjects used in this study were collected and processed following the TBI Biospecimen Collection Protocol listed in the NINDS traumatic brain injury common data element (CDE) webpage (https://commondataelements.ninds.nih.gov/TBI.aspx#tab=Data_Standards).
They follow the recommendations from the NIH-NINDS CDE Biospecimens and Biomarkers
Working Group. 1 This is the same protocol used in the TRACK-TBI pilot study for other biomarker analysis. 2, 3 . Briefly, the protocol includes the following key features: Blood biosamples (5-10 mL) were drawn into K2-EDTA vacutainer tubes. 4 Blood sample tubes were then spun at 5,000 rpm at room temperature for 5-7 minutes. The cleared plasma (top) fractions were pipetted and stored in 0.5-1.0 mL aliquots in polypropylene microcentrifuge tubes or cryofreeze tubes (1.5-2.0 mL capacity). Plasma sample tubes were then placed in ultra-low freezers at or below -80û C. An inventory system was established for tracking provenance of samples, including the time of collection, processing, storage, and number of times a biosample was thawed and refreezed.
Generally, samples used have gone through no more than two freeze-thaw cycles.
Finally, the frozen specimens were shipped to biomarker analysis site with ample amount of dry ice in insulated Styrofoam containers during air shipment using overnight courier service.
T-tau and P-tau standard characterization and quantification.
Recombinant human tau protein (N2R4 isoform with 441 residue) is from R-peptide Co.
(Cat. # T-1001-1) and used as total-tau (T-tau standard). Recombinant tau protein GSK3β phosphorylated (tau protein co-expressed with GSK3β in E coli cells) was from SignalChem Co. (Cat # T08-50FN) and used as P-tau standard. Both human T-tau and Ptau preparations were checked for purity by loading 2 µg on SDS-PAGE and stained with
Coomassie Blue and densitometrically scanned with NIH Image J software and we determined to be > 95% pure based on major T-tau or P-tau band intensity over background and other minor bands. In addition, T-tau and P-tau were determined by immunoblots to be both reactive at DA9 and DA31 monoclonal antibodies (Mabs) while only P-tau was reactive to anti-P-tau (pThr-231) RZ3 Mab. For P-tau, since in this preparation, the P-tau is co-expressed in vivo with GSK3β, an established tau kinase in the brain, this P-tau preparation has multiple phosphorylation sites (such as Thr-231, Ser-202, Ser396/404). However, for quantification as standard, we needed to examine if the percentage of Thr-231 site was phosphorylated. To accomplish this, we used the following ELISA set up a various amount of Thr-231 peptide (1 pg/mL -50 ng/mL) (used to produce standard curve) and two known concentrations of P-tau preparations in coating buffer (sodium carbonate buffer; 100 µL) into individual wells of a 96-well ELISA plate overnight, followed by washing with TBST (Tris buffer saline with 0.04%
Tween-20) and the addition of RZ3 Mab (1/1,000 dilution) in TBST buffer for 3 hours.
Following washing, immunoreactivity was determined with TMB substrate (Pierce).
Based on this method, and the amount of P-tau loaded, we calculated the P-Thr-231ÐT-tau molar ratio to be between 0.9 Ð 1.3 (three determinations). Thus, we concluded that the T-231 site in the P-tau preparation used is fully phosphorylated. Finally, the actual concentrations of T-tau and P-tau preparations are determined by the absorbance at 280 nm of 0.5 mg/mL T-tau and P-tau stock solutions using a spectrophotometer (Molecular Devices Spectromax 190 with a quartz 96-well flat-bottom plate with light path of 0.5 cm in each well) and calculated extinction coefficient of 7,575 M -1 cm -1 for both T-tau and Ptau.
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Plasma P-tau and T-tau analysis by Enhanced Immunoassay using Multi-Arrayed
Fiberoptics conjugated with rolling circle amplification.
Enhanced Immunoassay using Multi-Arrayed Fiberoptics (EIMAF) conjugated with rolling circle amplification (a-EIMAF) was used to measure the T-tau and P-tau levels in de-identified human plasma samples. 5 All assays were performed blind to cohort status.
Briefly, high-binding 96-well microtiter plates were coated with a capture anti-tau Mab at 6 µg/ml final concentration [Mab DA31 (directed against aa150-190 of human tau-441)
for T-tau and Mab RZ-3 for P-tau (P-Thr231)]. 6 Proteins in plasma aliquots diluted with phosphate-buffered saline (PBS) were detected by the addition of biotinylated Mab DA9
(aa 102-140) (4 µg/ml) followed by streptavidin, a biotinylated DNA primer (5'-TTTTTTTGTCCGTGCTAGAAGGAAACAGTTAC-3') and a T4-DNA ligasepretreated prostate DNA template. 7 Rolling circle amplification was initiated by adding nucleotide triphosphates supplemented with dUTP-Texas Red and φ29 DNA polymerase.
Incubation for several hrs was followed by PBS-0.1% Tween 20 washes, addition of 1N NaOH, neutralization with 1 M Tris-HCl, pH 7.5, heat treatment (100¡ C for 15 min). A 90 µL sample was drawn up into a 100 µL microcap (Drummond Scientific) microcapillary tube, which was then inserted into a specially designed tube sample holder for laser excitation and emission quantitation using our multi-arrayed fiber optic technology.
For each sample, a round of testing involved assaying the sample in triplicate. In cases where additional sample volumes were available, further rounds of testing (up to 2 additional rounds) might be carried out in independent studies. Raw data signals are in µvolt unit. T-tau and P-tau data from identical sample are averaged. Using a standard © 2017 American Medical Association. All rights reserved. 5
curve within the linear concentration range of analyte, T-tau and P-tau data are converted back to fg/mL (See eFigures 1 and 2). Intraassay %CV for T-tau and P-tau are 5.51% and 3.50%, respectively; interassay %CV for T-tau and P-tau are 5.16% and 6.96%, respectively, for the qualification range. The lower limit of detection (LLOD) for T-tau and P-tau are 0.0001 fg/mL and 0.00001 fg/mL, respectively, while lower limit of quantification (LLOQ) for T-tau and P-tau are 0.0001 fg/mL and 0.00001 fg/mL, respectively (eFigures 1 and 2).
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eFigure 1. Standard Curve for T-tau Assay (a-EIMAF)
A range of qualified recombinant T-tau was assayed with a-EIMAF format. Group T-tau, P-tau and P-tauÐT-tau ratio are shown as mean + SEM (n), as well as median, lower limit, upper limit are shown. Corresponding ROC curves shown in Figure 1D .
© 2017 American Medical Association. All rights reserved. 14 eTable 5. Acute Plasma P-tau, T-tau and P-tauÐT-tau Ratio ROC Curve Characterization for CT+ vs. CT-. Corresponding ROC curves shown in Figure 2D .
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